<div id="readability-page-1"><p><span>Krystal Biotech (NASDAQ:KRYS - Get Free Report)</span> had its price target boosted by research analysts at TD Cowen  from $202.00 to $306.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a &#34;buy&#34; rating on the stock. TD Cowen's price objective points to a potential upside of 17.52% from the stock's previous close.</p><div><p><span></span><span>Get <strong>Krystal Biotech</strong> alerts:</span></p></div><ul><li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li></ul><p>Other equities analysts have also issued research reports about the company. Zacks Research upgraded Krystal Biotech from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Wednesday. Cowen  reiterated a &#34;buy&#34; rating on shares of Krystal Biotech in a research report on Friday. HC Wainwright  restated a &#34;buy&#34; rating and issued a $310.00 target price (up from $240.00) on shares of Krystal Biotech in a research note on Friday. Bank of America lifted their price target on Krystal Biotech from $182.00 to $255.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, October 17th. Finally, Chardan Capital raised their target price on shares of Krystal Biotech from $216.00 to $220.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, November 4th. One investment analyst  has rated the stock with a Strong Buy rating, nine have given a Buy rating and one  has given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of &#34;Buy&#34; and an average price target of $260.50.</p><p><b>View Our Latest Stock Analysis on Krystal Biotech</b></p><h2>Krystal Biotech Stock Performance</h2><ul><li>Krystal Clear: Krystal Biotech Clears Resistance in Good Volume</li></ul><p>Shares of NASDAQ KRYS traded up $11.47 during trading hours on Friday, hitting $260.38. The company's stock had a trading volume of 197,700 shares, compared to its average volume of 299,341. Krystal Biotech has a 12 month low of $122.80 and a 12 month high of $267.48. The business has a 50-day simple moving average of $226.28 and a 200-day simple moving average of $181.50. The stock has a market cap of $7.55 billion, a price-to-earnings ratio of 39.04 and a beta of 0.46. </p><p>Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, November 3rd. The company reported $2.66 EPS for the quarter, topping analysts' consensus estimates of $1.12 by $1.54. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. The business had revenue of $97.80 million during the quarter, compared to analysts' expectations of $93.72 million.  On average, equities research analysts forecast that  Krystal Biotech will post 6.14 EPS for the current year. </p><h2>Insider Transactions at Krystal Biotech</h2><p>In related news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the transaction, the insider owned 1,413,711 shares in the company, valued at $311,242,613.76. The trade was a 1.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. 13.70% of the stock is owned by insiders. </p><h2>Institutional Inflows and Outflows</h2><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Hantz Financial Services Inc. increased its stake in  Krystal Biotech by 8,950.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 181 shares of the company's stock worth $25,000 after buying an additional 179 shares in the last quarter.  Bessemer Group Inc. raised its holdings in shares of  Krystal Biotech by 106.9% during the third quarter. Bessemer Group Inc. now owns 149 shares of the company's stock worth $26,000 after acquiring an additional 77 shares in the last quarter.  AdvisorNet Financial Inc bought a new position in shares of  Krystal Biotech during the 3rd quarter worth about $30,000.  Salomon &amp; Ludwin LLC acquired a new stake in  Krystal Biotech during the 3rd quarter worth $33,000.  Finally, First Horizon Advisors Inc. boosted its position in shares of  Krystal Biotech by 212.8% in the second quarter. First Horizon Advisors Inc. now owns 244 shares of the company's stock valued at $34,000 after acquiring an additional 166 shares during the period. 86.29% of the stock is currently owned by institutional investors. </p><h2>Krystal Biotech Company Profile</h2> (Get Free Report)<p>Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.  </p><p>The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Krystal Biotech</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>Do not delete, read immediately</li><li>This stock gets a 94 out of 100</li><li>First Time Since 2007: All Warnings Active</li><li>How the Rich Retire</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1JZUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1JZUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Krystal Biotech Right Now?</h2><p>Before you consider Krystal Biotech, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.</p><p>While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

KRYS

<p>TD Cowen raised its price target for Krystal Biotech (NASDAQ:KRYS) from $202.00 to $306.00, maintaining a "buy" rating. This suggests a potential upside of 17.52% from the previous close. Other analysts have also upgraded their ratings, with Zacks Research moving from "hold" to "strong-buy" and HC Wainwright setting a target of $310.00. The stock traded at $260.38, with a market cap of $7.55 billion and a P/E ratio of 39.04. Krystal Biotech reported strong earnings, exceeding estimates with $2.66 EPS and $97.80 million in revenue.</p>

Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $306.00 at TD Cowen